Evidence map›Paper›PMID 25188323›Full record

ArticleBritish journal of cancer2014

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

A Linton, N Pavlakis, R O'Connell, M Soeberg, S Kao, S Clarke, J Vardy, N van Zandwijk

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016
    Guideline
  3. Trial
  4. Observational
  5. Article
  6. An Evaluation Into the Robustness of Grading of Pleural Mesothelioma Outside of Specialist Centres.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

A Linton1] Asbestos Diseases Research Institute (ADRI), University of Sydney, PO Box 3628, Rhodes, NSW 2139, Australia [2] Concord Cancer Centre, Sydney, Concord, NSW 2139, Australia [3] Sydney Medical School, University of Sydney, Sydney, Australia.
N Pavlakis1] Sydney Medical School, University of Sydney, Sydney, Australia [2] Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
R O'Connell1] NHMRC Clinical Trials Centre, Camperdown, NSW 2050, Australia [2] Sydney Cancer Centre, Camperdown, NSW 2050, Australia.
M Soeberg1] Asbestos Diseases Research Institute (ADRI), University of Sydney, PO Box 3628, Rhodes, NSW 2139, Australia [2] Sydney Medical School, University of Sydney, Sydney, Australia [3] Cancer Institute NSW, Alexandria, Sydney, NSW 1435, Australia.
S Kao1] Asbestos Diseases Research Institute (ADRI), University of Sydney, PO Box 3628, Rhodes, NSW 2139, Australia [2] Sydney Medical School, University of Sydney, Sydney, Australia.
S Clarke1] Sydney Medical School, University of Sydney, Sydney, Australia [2] Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
J Vardy1] Concord Cancer Centre, Sydney, Concord, NSW 2139, Australia [2] Sydney Medical School, University of Sydney, Sydney, Australia.
N van Zandwijk1] Asbestos Diseases Research Institute (ADRI), University of Sydney, PO Box 3628, Rhodes, NSW 2139, Australia [2] Sydney Medical School, University of Sydney, Sydney, Australia.
Asbestos Diseases Research Institute · AURoyal North Shore Hospital · AUCooperative Trials Group for Neuro-Oncology · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the prognosis of most patients presenting with malignant pleural mesothelioma (MPM) is poor, a small proportion survives long term. We investigated factors associated with survival in a large patient series.

methodsAll patients registered with the NSW Dust Diseases Board (2002-2009) were included in an analysis of prognostic factors using Kaplan-Meier and Cox regression analysis. On the basis of these analyses, we developed a risk score (Prognostic Index (PI)).

resultsWe identified 910 patients: 90% male; histology (epithelioid 60%; biphasic 13%; sarcomatoid 17%); stage (Tx-I-II 48%; III-IV 52%); and calretinin expression (91%). TREATMENT: chemotherapy(CT) 44%, and extrapleural-pneumonectomy (EPP) 6%. Median overall survival (OS) was 10.0 months. Longer OS was associated with: age <70 (13.5 vs 8.5 months; P<0.001); female gender (12.0 vs 9.9 months; P<0.001); epithelioid subtype (13.3 vs 6.2 months; P<0.001); ECOG status 0 (27.4 vs 9.7 months; P=0.015), calretinin expression (10.9 vs 5.5 months; P<0.001); neutrophil-lymphocyte ratio (NLR) <5 (11.9 vs 7.5 months; P<0.001); platelet count <400 (11.5 vs 7.2 months; P<0.001); and normal haemoglobin (16.4 vs 8.8 months; P<0.001). On time-dependent analysis, patients receiving pemetrexed-based chemotherapy (HR=0.83; P=0.048) or EPP (HR=0.41; P<0.001) had improved survival. Age, gender, histology, calretinin and haematological factors remained significant on multivariate analysis. In all, 24% of patients survived >20 months: 16% of these receiving EPP, and 66% CT. The PI offered improved prognostic discrimination over one of the existing prognostic models (EORTC).

conclusionsWe identified calretinin expression, age, gender, histological subtype, platelet count and haemoglobin level as independent prognostic factors. Patients undergoing EPP or pemetrexed-based chemotherapy demonstrated better survival, but 84% and 34% of long survivors, respectively, did not receive radical surgery or chemotherapy.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsLymphocytesMaleMesotheliomaMesothelioma, MalignantNeoplasm StagingNeutrophilsNew South WalesPleural NeoplasmsPneumonectomy

Identifiers

PMID25188323
PMCPMC4453733
OpenAlexW1984633408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.